India Medtronic Pvt Ltd, a wholly owned subsidiary of Medtronic plc, has collaborated with Eris Lifesciences, one of the leading players in the chronic drugs segment, for a diabetes monitoring initiative in India. This is a first of its kind collaborative initiative in the country between a pharmaceutical and medical device company. Under the collaboration, both companies will be utilizing their respective strengths to help patients monitor their diabetes better.
Medtronic will bring to India Guardian Connect, its latest US FDA approved device, for real-time evaluation of glucose variability in diabetes patients, while Eris will offer the device at clinics and healthcare delivery units under its patient care initiative.
Amit Bakshi, Chairman and Managing Director, Eris Lifesciences, said, "For better patient outcomes in diabetes, we believe that a holistic approach to medicine, diet and continuous monitoring is important. Technology has emerged as a great enabler in healthcare. While technology is transforming healthcare delivery, on the patient and physician end there is a need to create more awareness of how to use technology and how technology can make managing diabetes easier. Through this initiative, we aim to make patients and physicians adopt newer technologies for better health."
Madan Krishnan, Managing Director & Vice President, India Medtronic Pvt Ltd, stated, "Medtronic's innovations in the space of Continuous Glucose Monitoring and Insulin Pumps have transformed diabetes management. Guardian Connect is a technological breakthrough that will change the diabetes treatment landscape. It empowers the patient to take control in real-time and the physician to be fully-equipped with data and evidence. In a large country like India, with a high incidence of diabetes, we are happy to align with a partner who understands the challenges of diabetes management and has the reach to take our solutions across the country."
